Lupin Limited
LUPIN
Classifica tra le azioni
#2103
Lupin Limited is a pharmaceutical firm dedicated to the creation,... Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
Prezzo delle azioni
$21.40
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$9.79B
Variazione (1 giorno)
-1.36%
Variazione (1 anno)
-3.02%
Paese
IN
Scambia Lupin Limited (LUPIN)
Categoria
Healthcare
Utile per Lupin Limited (LUPIN)
Utile nel Jun 2026 TTM: $824.86M
Secondo gli ultimi rapporti finanziari di Lupin Limited, gli utili attuali della società sono $824.86M. Nel 2024, la società ha registrato un utile di $290.50M, un aumento rispetto a agli utili del 2023, che erano di $87.18M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Lupin Limited dal 2004 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $824.86M | 75.71% |
| 2025 | $469.45M | 61.60% |
| 2024 | $290.50M | 233.20% |
| 2023 | $87.18M | -148.23% |
| 2022 | $-180.77M | -178.93% |
| 2021 | $229.01M | 127.84% |
| 2020 | $100.52M | -50.46% |
| 2019 | $202.90M | 141.60% |
| 2018 | $83.98M | -84.63% |
| 2017 | $546.37M | 8.74% |
| 2016 | $502.47M | -8.18% |
| 2015 | $547.26M | -3.94% |
| 2014 | $569.71M | 60.84% |
| 2013 | $354.21M | 50.17% |
| 2012 | $235.88M | 5.71% |
| 2011 | $223.13M | 19.92% |
| 2010 | $186.07M | 55.87% |
| 2009 | $119.38M | -11.57% |
| 2008 | $135.00M | 43.62% |
| 2007 | $93.99M | 85.65% |
| 2006 | $50.63M | 132.81% |
| 2005 | $21.75M | -50.60% |
| 2004 | $44.02M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 113.92% |
IN
|
